Semaglutide and Tirzepatide Linked to Allodynia and Dysesthesia: New Safety Signal
Case series reports allodynia (pain from light touch) and dysesthesia (abnormal sensations) associated with semaglutide and tirzepatide use, identifying a previously unreported neurological side effect.
Quick Facts
What This Study Found
Allodynia and dysesthesia identified as previously unreported neurological side effects of semaglutide and tirzepatide, likely related to GLP-1/GIP receptor effects on sensory neurons.
Key Numbers
Previously reported with semaglutide; this report adds the first tirzepatide case. Both drugs are commonly prescribed for T2DM and weight management.
How They Did This
Case series documenting allodynia and dysesthesia in patients receiving semaglutide or tirzepatide. Clinical presentation, temporal association, and potential mechanisms described.
Why This Research Matters
Millions of people take these drugs. Identifying new neurological side effects — even uncommon ones — is critical for patient safety and informed prescribing.
The Bigger Picture
As GLP-1 drugs are used by more people for longer periods, rare side effects will emerge. Neurological symptoms like allodynia suggest these drugs have broader effects on the nervous system than initially appreciated — consistent with GLP-1 receptor expression throughout the nervous system.
What This Study Doesn't Tell Us
Case series cannot prove causation. Allodynia and dysesthesia have many possible causes. The symptoms may be coincidental or related to other medications, weight loss, or underlying conditions.
Questions This Raises
- ?What is the incidence of allodynia/dysesthesia with GLP-1 drugs in larger datasets?
- ?Are the symptoms reversible upon drug discontinuation?
- ?Does the mechanism involve direct GLP-1R activation on sensory neurons or indirect metabolic changes?
Trust & Context
- Key Stat:
- New side effect identified Allodynia (touch pain) and dysesthesia (abnormal sensations) reported with semaglutide and tirzepatide — a previously unrecognized neurological effect
- Evidence Grade:
- Preliminary evidence: case series identifying a new safety signal. Incidence and causation need confirmation in larger studies.
- Study Age:
- Published in 2025. Important new pharmacovigilance signal for widely used GLP-1/GIP drugs.
- Original Title:
- Allodynia and Dysesthesia Associated With Semaglutide and Tirzepatide.
- Published In:
- Cureus, 17(10), e94126 (2025)
- Authors:
- Ahern, Susan
- Database ID:
- RPEP-09789
Evidence Hierarchy
Frequently Asked Questions
Can semaglutide cause pain or tingling?
This case series reports allodynia (pain from light touch) and dysesthesia (abnormal sensations) in some patients on semaglutide and tirzepatide. It appears to be uncommon. If you experience these symptoms, report them to your doctor — they may be drug-related.
Should I stop my GLP-1 drug if I get tingling?
Do not stop medication without consulting your doctor. Tingling has many possible causes, and stopping GLP-1 drugs abruptly can cause blood sugar rebound. Report the symptoms so your doctor can evaluate whether they are drug-related and whether dose adjustment is needed.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09789APA
Ahern, Susan. (2025). Allodynia and Dysesthesia Associated With Semaglutide and Tirzepatide.. Cureus, 17(10), e94126. https://doi.org/10.7759/cureus.94126
MLA
Ahern, Susan. "Allodynia and Dysesthesia Associated With Semaglutide and Tirzepatide.." Cureus, 2025. https://doi.org/10.7759/cureus.94126
RethinkPeptides
RethinkPeptides Research Database. "Allodynia and Dysesthesia Associated With Semaglutide and Ti..." RPEP-09789. Retrieved from https://rethinkpeptides.com/research/ahern-2025-allodynia-and-dysesthesia-associated
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.